India's new limits cover 137 cancer drugs, but Jemperli did not receive a price cut. Keeping its manufacturer price unchanged modestly supports GSK, though the wider rules create price risk for other medicines.
That leaves GSK's reported price for Jemperli in India intact, avoiding the immediate sales pressure a cut could bring. The caps cover many cancer medicines, but the source reports no cut to Jemperli.
Follow GlaxoSmithKline (GSK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GSK